# Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

> **NCT04236960** · PHASE1 · COMPLETED · sponsor: **Walvax Biotechnology Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Meningococcal Group ACYW135 Conjugate Vaccine

## Key facts

- **NCT ID:** NCT04236960
- **Lead sponsor:** Walvax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-17
- **Primary completion:** 2019-09-16
- **Final completion:** 2019-11-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04236960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04236960, "Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04236960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*